Analysis of Tubespins as a suitable scale‐down model of bioreactors for high cell density CHO cell culture

High cell density (HCD) culture increases recombinant protein productivity via higher biomass. Compared to traditional fed‐batch cultures, HCD is achieved by increased nutrient availability and removal of undesired metabolic components via regular medium replenishment. HCD process development is usually performed in instrumented lab‐scale bioreactors (BR) that require time and labor for setup and operation. To potentially minimize resources and cost during HCD experiments, we evaluated a 2‐week 50‐mL Tubespin (TS) simulated HCD process where daily medium exchanges mimic the medium replacement rate in BR. To best assess performance differences, we cultured 13 different CHO cell lines in simulated HCD as satellites from simultaneous BR, and compared growth, metabolism, productivity and product quality. Overall, viability, cell‐specific productivity and metabolism in TS were comparable to BR, but TS cell growth and final titer were lower by 25 and 15% in average, respectively. Peak viable cell densities were lower in TS than BR as a potential consequence of lower pH, different medium exchange strategy and dissolved oxygen limitations. Product quality attributes highly dependent on intrinsic molecule or cell line characteristics (e.g., galactosylation, afucosylation, aggregation) were comparable in both scales. However, product quality attributes that can change extracellularly as a function of incubation time (e.g., deamidation, C‐terminal lysine, fragmentation) were in general lower in TS because of shorter residence time than HCD BR. Our characterization results and two case studies show that TS‐simulated HCD cultures can be effectively used as a simple scale‐down model for relative comparisons among cell lines for growth or productivity (e.g., clone screening), and for investigating effects on protein galactosylation. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:490–499, 2017

[1]  A. Quarteroni,et al.  Use of orbital shaken disposable bioreactors for mammalian cell cultures from the milliliter-scale to the 1,000-liter scale. , 2009, Advances in biochemical engineering/biotechnology.

[2]  Suzanne S Farid,et al.  Fed‐batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty , 2013, Biotechnology and bioengineering.

[3]  Lisa Connell-Crowley,et al.  The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development , 2015, mAbs.

[4]  Difei Qiu,et al.  C‐terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes , 2008, Biotechnology and bioengineering.

[5]  Philippe Girard,et al.  TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology , 2004 .

[6]  W. Hsu,et al.  Advanced microscale bioreactor system: a representative scale-down model for bench-top bioreactors , 2012, Cytotechnology.

[7]  A. Sreedhara,et al.  Effect of ambient light on monoclonal antibody product quality during small‐scale mammalian cell culture process in clear glass bioreactors , 2014, Biotechnology progress.

[8]  S. Gupta,et al.  Effects of Elevated pCO2 and Osmolality on Growth of CHO Cells and Production of Antibody‐Fusion Protein B1: A Case Study , 2008, Biotechnology progress.

[9]  D. Lütkemeyer,et al.  Mapping and partial characterization of proteases expressed by a CHO production cell line , 2006, Biotechnology and bioengineering.

[10]  Konstantin B Konstantinov,et al.  The future of industrial bioprocessing: batch or continuous? , 2015, Biotechnology and bioengineering.

[11]  Weichang Zhou,et al.  Development and application of a high-throughput platform for perfusion-based cell culture processes. , 2015, Journal of biotechnology.

[12]  K. Xie,et al.  On-line monitoring of oxygen in Tubespin, a novel, small-scale disposable bioreactor , 2011, Cytotechnology.

[13]  Christopher Miller,et al.  High‐throughput miniaturized bioreactors for cell culture process development: Reproducibility, scalability, and control , 2014, Biotechnology progress.

[14]  P. V. van Berkel,et al.  Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose , 2011, Biotechnology and bioengineering.

[15]  D K Robinson,et al.  Characterization of a recombinant antibody produced in the course of a high yield fed‐batch process , 1994, Biotechnology and bioengineering.

[16]  Marcella Yu,et al.  Effects of cell culture conditions on antibody N‐linked glycosylation—what affects high mannose 5 glycoform , 2011, Biotechnology and bioengineering.

[17]  Jun Luo,et al.  Probing of C‐terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media , 2012, Biotechnology and bioengineering.

[18]  W. Miller,et al.  Production of tPA in recombinant CHO cells under oxygen‐limited conditions , 1993, Biotechnology and bioengineering.

[19]  Chung-Jr Huang,et al.  A robust method for increasing Fc glycan high mannose level of recombinant antibodies , 2015, Biotechnology and bioengineering.